Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.

doi:10.1002/cam4.3649

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.

Cancer medicine - 1 Apr 2021

Shi Yunfei, Lei Youming, Liu Li, Zhang Shiyue, Wang Wenjing, Zhao Juan, Zhao Songhui, Dong Xiaowei, Yao Ming, Wang Kai, Zhou Qing

Abstract excerpt

OBJECTIVES: This study aimed to explore the novel biomarkers for immune checkpoint inhibitor (ICI) responses in non-small cell lung cancer (NSCLC) by integrating genomic profiling, tumor mutational burden (TMB), and expression of programmed death receptor 1 ligand (PD-L1). MATERIALS AND METHODS: Tumor and blood samples from 637 Chinese patients with NSCLC were collected for targeted panel sequencing. Genomic...

Topics

Aged
Anaplastic Lymphoma Kinase
B7-H1 Antigen
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
China
Female
Gene Rearrangement
Genes, erbB-1
Genes, p53

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Genes, ras

Genetic Markers

Genetic Profile

High-Throughput Nucleotide Sequencing

Histone-Lysine N-Methyltransferase

Humans

Immune Checkpoint Inhibitors

Immunotherapy, Adoptive

Source

Open in PubMed Open full text

Identifiers

PMID: 33655698
DOI: 10.1002/cam4.3649
PMCID: PMC7982619

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.PMID 33655698Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancerSemantic proximity Read ↗

Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.Semantic proximity Read ↗

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer.Semantic proximity Read ↗

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival OutcomesSemantic proximity Read ↗

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.Semantic proximity Read ↗

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.Semantic proximity Read ↗

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer.Semantic proximity Read ↗

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.